Hypertension: Review of cohort study: Common hypertension drugs may reduce risk of colorectal cancer

Drugs commonly used to treat high blood pressure also reduce the risk ofcolorectal cancer, according to a new study published July 5 in the Journal of the American Heart Associationdrugs such as vasculartensionin conversion enzyme inhibitors (ACE-i) or angiotensin II blockers (ARB) are used to treat diseases such as heart failure, hypertension or heart diseaseThese drugs can inhibit or block angiotensin, a chemical that causes arterial stenosisDoctors usually prescribe these drugs to patients with high blood pressure to relax and stretch blood vessels, thereby lowering blood pressureaccording to the large study, taking these drugs may also reduce the risk of colorectal cancerColorectal cancer is the third most common cancer and the second leading cause of cancer death worldwide"The role of ACE inhibitors and ARBs in cancer development is controversial and, in some cases, contradictory," said DrWai KLeung, a clinical professor at the University of China and ChinaofPrevious studies have been limited by several factors, including the small number of patients and data only in short-term follow-upOur findings provide new insights into the potential role of these drugs inprevention of colorectal cancer This is the first study to show the potential beneficial effects of ACE inhibitors and ARBs on the development of colorectal cancer, and is based on a large number of patients who did not develop colorectal cancer at the beginning of the study "
this is a territory-wide retrospective cohort study in which researchers reviewed the health records of 187,897 adult (over or equal) adult (40-year-old) patients in Hong Kong between 2005 and 2013, all of whom had negative baseline colonoscopy for colorectal cancer Exclusion criteria include colonoscopy of colorectal cancer found to be less than 6 months old, previous colorectal cancer, inflammatory bowel disease and colonectomy The main result was 6 to 36 months after a colonoscopy
diagnosed colorectal cancer colorectal cancer is divided into near end (near end of spleen) and distant end cancer Using angiotensin conversion enzyme inhibitor/angiotensin receptor blocker (used in the 5 years prior to colonoscopy, 180 days), 23 covariate variables (including patient factors, simultaneous medication and endoscopy center performance) were used to adjust the trend score regression to obtain an adjusted risk ratio for colorectal cancer of 187,897 eligible patients, 30856 (16.4%) were ACE inhibitor/angiotensin receptor blockers 854 cases (0.45%) had colorectal cancer between 6 and 36 months after an exponential colonoscopy (near end cancer: 147 cases (17.2%) These drugs were associated with a lower risk of colorectal cancer for less than 3 years after an exponential colonoscopy (correction risk ratio, 0.78, 0.64-0.96), but not with a risk of colorectal cancer occurring for more than 3 years (correction risk ratio, 1.18, 0.88-1.57); Angiotensin conversion enzyme inhibitors/angiotensin receptor blockers are associated with a lower risk of colorectal cancer Analysis: those who took high blood pressure drugs such as ACE-i or ARBs had a 22 percent lower risk of colorectal cancer over the next three years The benefits of ACE-i and ARBs are found in patients aged 55 or above and patients with a history of colon polyps; "While patients with high blood pressure, heart failure and kidney disease are taking ACE-i and ARBs, reducing the risk of colorectal cancer may be another factor that doctors consider when choosing antihypertensive drugs," Says Leung this is a retrospective study that looks at whether patients taking these drugs develop colorectal cancer The researchers note that the results should be validated by a prospective randomized controlled study that will actively track patients to determine the potential benefits of these drugs to the risk of colorectal cancer